Indium (111In) biciromab

Indium (¹¹¹In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.^[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,^[2] but was withdrawn during clinical trials.^[3]

References

↑ King, David J.; John R. Adair (1999). "Recombinant antibodies for the diagnosis and therapy of human disease". Current Opinion in Drug Discovery & Development. 2 (2): 112. ISSN 1367-6733.
↑ Answers.com: Centocor Ortho Biotech Products, L.P.
↑ DiagnosticImaging.com: Centocor withdraws imaging agent applications

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Erenumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Humanized ("-anibizu-")	Ranibizumab

Human ("-gru-")	Bimagrumab

Humanized ("-grozu-")	Domagrozumab Landogrozumab

This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.